Abstract
Renal Cell Carcinoma (RCC), composed of various subtypes, faces a prognostic prediction challenge. Ferroptosis, an emerging cell death form, has been considered as a vital factor for the development of cancer. However, it remains a further exploration of the predictive value for ferroptosis-correlated genes in RCC. In our work, we paid attention to the gene expression data related to clinical profiles of RCC patients which derived from public databases, TCGA and ICGC. The least absolute shrinkage and selection operator (LASSO) Cox regression performed to establish an optimally predictive model based on the TCGA data. The RCC patients derived from ICGC applied to the validation of the predictive model above. Under expectation, our observation indicated that major ferroptosis-correlated genes (75%) expressed significantly between tumorous and adjacently normal cells in the TCGA cohort. Combined with the differentially expressed genes (DEGs) (P< 0.05) and overall survival (OS), there were twenty-seven genes eventually approached the subsequent analyses. With the optimal 12-genes model screened by LASSO analysis, we aimed to classify RCC patients into the high-risk or low-risk groups based on the median scores. And we created a novel predictive model based on the 12-genes’ risk score. Compared with the two groups, our work discovered that patients in the high-risk group presented more observably shrunken OS than the low (P < 0.05). Through the multivariate cox regression, the predictive model became an independent risk factor in OS (HR =2.053, P<0.001). Moreover, the receiver operating characteristic (ROC) curve proved the significantly predictive value for our predictive model. Functional research unexpectedly showed the immune cells and immune function pathways enriched differently, which emphasized the immune role for the progress of RCC. In a word, an emerging ferroptosis-correlated signature might be popular for medical prediction in RCC. The targeted treatment on ferroptosis may be a potential schedule for RCC.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors